NPPB and axial length measurement: Biomarkers such as B-type natriuretic peptide (BNP), N-terminal fragment of the pro-brain natriuretic peptide (NT-proBNP), and high sensitivity cardiac troponin have demonstrated utility in detecting cardiac involvement, predicting prognosis, and evaluating treatment response in patients with systemic immunoglobulin light chain amyloidosis (AL) (Law et al., 2016[72]; Manwani et al., 2018[82]; Kero et al., 2020[63]; Ren et al., 2021[110]).